Efficacy Analysis of Combination of Moxifloxacin and Glucocorticoids in Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Dis-ease
Objective To study the effect and value of moxifloxacin combined with glucocorticoid in the treatment of acute exacerbation of chronic obstructive pulmonary disease(AECOPD).Methods The clinical data of 46 AECOPD patients admitted to Dongchangfu District Hospital of Traditional Chinese Medicine in Liaocheng City from December 2022 to December 2023 were retrospectively selected and divided into a study group and a control group based on the difference in therapies,with 23 cases in each group.The control group was treated with salmeterol ticarcoson powder inhaler,and the study group was treated with moxifloxacin based on the control group.Efficacy,lung function,and in-flammatory factors were compared between the two groups.Results The total effective rate of the study group was 100.00%,which was higher than 73.91%of the control group,and the difference was statistically significant(χ2=4.792,P<0.05).The lung function indexes and inflammatory factor levels of the study group were better than those of the control group,and the differences were statistically significant(all P<0.05).Conclusion Moxifloxacin+glucocorti-coid combination is effective in the treatment of AECOPD,improving patients'lung function indexes,inflammation level,and enhancing the efficacy.
MoxifloxacinSulidieAcute exacerbation of chronic obstructive pulmonary diseasePulmonary function
NETL
NSTL
万方数据
